Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Neuropathy - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Diabetic Neuropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Neuropathy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Neuropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Diabetic Neuropathy Overview 10 Therapeutics Development 11 Pipeline Products for Diabetic Neuropathy - Overview 11 Pipeline Products for Diabetic Neuropathy - Comparative Analysis 12 Diabetic Neuropathy - Therapeutics under Development by Companies 13 Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes 15 Diabetic Neuropathy - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Diabetic Neuropathy - Products under Development by Companies 19 Diabetic Neuropathy - Products under Investigation by Universities/Institutes 20 Diabetic Neuropathy - Companies Involved in Therapeutics Development 21 Araim Pharmaceuticals Inc. 21 Bristol-Myers Squibb Company 22 Cebix Incorporated 23 Celgene Corporation 24 Glucox Biotech AB 25 Longevity Biotech, Inc 26 Lpath, Inc. 27 Neuralstem, Inc. 28 NovaLead Pharma Pvt. Ltd. 29 Nuvo Research Inc. 30 Omeros Corporation 31 Pfizer Inc. 32 R-Tech Ueno, Ltd. 33 Reata Pharmaceuticals, Inc. 34 Relief Therapeutics S.A. 35 Sumitomo Dainippon Pharma Co., Ltd. 36 Virobay Inc. 37 ViroMed Co., Ltd. 38 Diabetic Neuropathy - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 atexakin alfa - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 benfotiamine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 BNV-222 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 CBX-129801 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 cibinetide - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 CMB-200 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Cyndacel-M - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Drug for Pain - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Flexicaine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ketoprofen - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 LBT-3627 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Lpathomab - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 NLP-198 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 NSI-566 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 OMS-721 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 PDA-002 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 PF-05089771 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 pirenzepine hydrochloride - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 ranirestat - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 RTA-901 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 RTU-1096 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Small Molecule to Agonize Kv7.2 for Neuropathic Pain and Diabetic Neuropathy - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecules for Diabetic Neuropathy - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 VBY-285 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 VM-202 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Diabetic Neuropathy - Recent Pipeline Updates 89 Diabetic Neuropathy - Dormant Projects 106 Diabetic Neuropathy - Discontinued Products 108 Diabetic Neuropathy - Product Development Milestones 109 Featured News & Press Releases 109 Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 109 Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 110 Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 111 Sep 07, 2011: Cebix To Chair Symposium On C-Peptide And Pathophysiology Of Diabetes At EASD Annual Meeting 111 May 11, 2011: Dainippon Sumitomo Pharma Announces Results Of Phase II Clinical Trial For Ranirestat For Diabetic Complications 112 Mar 18, 2011: ViroMed Enrolls Final Patient for US VM202-DPN Phase I/II Clinical Trial 113 Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 113 Sep 29, 2005: Dainippon and Eisai Signs Licensing Agreement for A Potential New Treatment For Diabetic Neuropathy 113 Appendix 115 Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 115 Disclaimer 116
List of Tables
Number of Products under Development for Diabetic Neuropathy, H2 2015 11 Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2015 12 Number of Products under Development by Companies, H2 2015 14 Number of Products under Investigation by Universities/Institutes, H2 2015 15 Comparative Analysis by Late Stage Development, H2 2015 16 Comparative Analysis by Clinical Stage Development, H2 2015 17 Comparative Analysis by Early Stage Development, H2 2015 18 Products under Development by Companies, H2 2015 19 Products under Investigation by Universities/Institutes, H2 2015 20 Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals Inc., H2 2015 21 Diabetic Neuropathy - Pipeline by Bristol-Myers Squibb Company, H2 2015 22 Diabetic Neuropathy - Pipeline by Cebix Incorporated, H2 2015 23 Diabetic Neuropathy - Pipeline by Celgene Corporation, H2 2015 24 Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H2 2015 25 Diabetic Neuropathy - Pipeline by Longevity Biotech, Inc, H2 2015 26 Diabetic Neuropathy - Pipeline by Lpath, Inc., H2 2015 27 Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H2 2015 28 Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2015 29 Diabetic Neuropathy - Pipeline by Nuvo Research Inc., H2 2015 30 Diabetic Neuropathy - Pipeline by Omeros Corporation, H2 2015 31 Diabetic Neuropathy - Pipeline by Pfizer Inc., H2 2015 32 Diabetic Neuropathy - Pipeline by R-Tech Ueno, Ltd., H2 2015 33 Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals, Inc., H2 2015 34 Diabetic Neuropathy - Pipeline by Relief Therapeutics S.A., H2 2015 35 Diabetic Neuropathy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 36 Diabetic Neuropathy - Pipeline by Virobay Inc., H2 2015 37 Diabetic Neuropathy - Pipeline by ViroMed Co., Ltd., H2 2015 38 Assessment by Monotherapy Products, H2 2015 39 Number of Products by Stage and Target, H2 2015 41 Number of Products by Stage and Mechanism of Action, H2 2015 43 Number of Products by Stage and Route of Administration, H2 2015 45 Number of Products by Stage and Molecule Type, H2 2015 47 Diabetic Neuropathy Therapeutics - Recent Pipeline Updates, H2 2015 89 Diabetic Neuropathy - Dormant Projects, H2 2015 106 Diabetic Neuropathy - Dormant Projects (Contd..1), H2 2015 107 Diabetic Neuropathy - Discontinued Products, H2 2015 108
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
